MARKET WIRE NEWS
  1. Home
  2. Stock
  3. CLDX
  4. News
  5. Celldex Surges After Completing Enrollments In Late
CLDX
Quote
Short
News
Articles
Message Board

Celldex surges after completing enrollments in late-stage trials for lead asset

Source: SeekingAlpha

2026-02-25 12:14:26 ET

More on Celldex

Read the full article on Seeking Alpha

For further details see:

Celldex surges after completing enrollments in late-stage trials for lead asset
Celldex Therapeutics Inc.

NASDAQ: CLDX

CLDX Trading

-1.99% G/L:

$31.46 Last:

136,693 Volume:

$31.94 Open:

mwn-ir Ad 300

CLDX Latest News

April 01, 2026 09:48:19 pm
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
April 01, 2026 04:01:00 pm
Celldex Announces Proposed Public Offering of Common Stock
March 27, 2026 10:30:00 am
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
March 01, 2026 09:45:00 am
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease

CLDX Stock Data

$1,661,236,775
63,525,694
0.16%
57
N/A
Biotechnology & Life Sciences
Healthcare
https://www.celldex.com
US
Hampton

Subscribe to Our Newsletter

Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.

Link Market Wire News to Your X Account

Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.

Download The Market Wire News App

Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.

Market Wire News iPhone App Market Wire News Android App